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Silk route to the acceptance and re-implementation  
of bacteriophage therapy
Expert round table on acceptance and re-implementation of bacteriophage therapy.
Rapid rise of antibiotic resistance has 
surged an increasing interest to devel-
op alternative treatments to counter 
bacterial infections. The worldwide 
use of antibiotics has been also as-
sociated with reduced microbiome 
diversity, which in turn has been re-
lated to malnutrition and several types 
of other diseases [1]. To avoid the 
return to a pre-antibiotic era, alterna-
tive treatments are urgently needed. 
Bacteriophage therapy is accepted 
and practiced in parts of Eastern 
 Europe, such as Russia, Georgia, and 
EU member state Poland. However, 
agreement has yet to be made in the 
rest of the world on a functional and 
practical legal frame-work that is flex-
ible enough to exploit and further ex-
plore the specificity of bacteriophages 
(phages) as an antibacterial, while 
giving precedence to patient safety. 
This paper arose through a series 
of workshops held during the confer-
ence “Phages as tools for therapy, 
prophylaxis and diagnostics” which 
took place in October 2015 in Tbilisi, 
Georgia. In order to evaluate the root 
cause of the actual delay of employing 
phage therapy in western countries, 
and to propose a solution, researchers, 
physicians, and industrial representa-
tives discussed the necessary aspects 
of phage therapy to be incorporated 
into contemporary policy. Since this 
topic affects society as a whole, a 
stakeholder analysis was conducted 
by identifying and classifying all par-
ties who are directly, or indirectly, in-
volved in re-implementation of phage 
therapy. Next, elements in the pre-
sent legal frame-work that the panel 
thought to be limiting, or even in-
hibiting, the re-introduction of phage 
therapy in western medicine were 
discussed, including topics such as 
intellectual property protection, clini-
cal trial design, production methods, 
and composition of phage cocktails. 
The use of phage therapy for both cu-
rative and prophylactic purposes was 
also evaluated and related safety and 
quality norms were classified in three 
categories: essential, important and 
desirable. Subsequently, the expert 
panel concluded on a proposal that 
could be taken by different stake-
holders and that also emphasizes the 
potential consequences for not imple-
menting phage therapy applications.
Stakeholder analysis
Inspired by Mitchel et al. [2], a stake-
holder analysis was conducted with 
the intention to position in a general 
context any group or individual who 
could affect or could be affected by 
the implementation of phage therapy 
(Supporting information, Table S1). 
The result of this analysis classifies na-
tional authorities and supra-national 
authorities as definitive stakeholders 
that can make significant influence on 
the implementation of phage therapy. 
Patients and patients’ organizations 
alongside medical doctors, research-
ers, and small biotech companies are 
classified as dependent stakehold-
ers, which means that although they 
are essential, removing the first hur-
dles for re-implementing the phage 
therapy is less dependent on these 
groups. Dormant stakeholders, like 
the established pharma industry, pos-
sess the power to impose their will, 
but their current involvement is lim-
ited by a lower degree of legitimacy 
or urgency. Dominant stakeholders, 
like politicians and health insurance 
companies, operate by a more for-
mal mechanism to whether accept 
or not new treatments such as phage 
therapy. Finally, religious leaders and 
ethicists are classified as discretion-
ary stakeholders whose insights can 
be considered as legitimate. However, 
the lack of power and urgency places 
these groups at a lower rank in the 
stakeholder hierarchy. 
Root cause analysis and actions  
to take
The fundamental reasons limiting, or 
even inhibiting, the application of the 
phage therapy in the western world 
in the 21st century are summarized 
in Table 1. As key hurdles we identi-
fied previous study set-ups, phage 
cocktail production methods and 
composition in context of the current 
legal frame-work, limitations in intel-
lectual property protection, and lack 
of awareness among (para-) medical 
staff and the general public. Table 1 
also lists the measures that can be 
taken by the identified stakeholders 
to overcome these restraints. National 
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phage therapy centers, operating un-
der the supervision of public health 
authorities and in interaction with 
private stakeholders, could be a driv-
ing force behind the implementation 
of the proposed measures [3]. 
Despite the long history of use of 
phage therapy in eastern European 
countries and our conviction that 
it can add significant value around 
the globe, the production process of 
phage products must satisfy minimal 
quality and safety norms before they 
could be used in clinical applications. 
Table 2 details a priority path of safety 
and quality norms for the produc-
tion of phage products and the ap-
plication of phage therapy in terms 
of essential, important, and desirable. 
Our recommendation for safe produc-
tion of phages deviates from current 
good manufacturing practices (GMP) 
requirements, which under the EU 
legislation require medicinal products 
including phage preparations to have 
a fixed, pre-defined composition. We 
reason that such legislation does not 
allow for the timely substitution of 
phage components and routine phage 
adaptation or phage “training”, and 
actually limits the exploration of the 
natural strength of the phage concept. 
Adapted phages, as applied for in-
stance at the Eliava Institute in Tbilisi, 
Georgia, are more effective in infect-
ing relevant pathogens and elicit less 
bacterial resistance to phages [4, 5]. 
In our opinion we could combine a 
flexible production process with the 
highest degree of safety by applying 
a GMP approach and hazard analysis 
critical control points (HACCP) as is 
done in the food industry, where every 
step of the manufacture, storage and 
distribution of the product is scien-
tifically analyzed for microbiological, 
physical and chemical hazards. To-
gether with well-defined release cri-
teria provided by modern analytical 
methods this approach would assure 
the absence of pathogenic host bacte-
rial strains, virulence factors such as 
endotoxins and unintended phages 
lysed from the host strain used in the 
phage replication. Although phage 
therapy has already been applied for 
many years without reported adverse 
effects in countries mentioned before, 
we further propose the installation 
of monitoring systems at the initial 
implementation of phage therapy. 
This would allow the collection of 
meta-data for prospective analyses 
and the evaluation of the efficacy of 
continuously adapted phage cocktails 
in treating existing and emerging 
pathogenic bacterial strains. 
In addition, we would like to pro-
mote the availability of large collec-
tions of well-characterized, therapeu-
tically important phages and their 
bacterial host strains as an efficient 
way to design safe phage cocktails 
and rapidly adjust them with the 
needs of the patients. Such collections 
already exist at well-known phage 
therapy centers or repositories: Eliava 
Institute of Bacteriophages, Microbi-
ology and Virology (IBMV, Georgia), 
Hirszfeld Institute of Immunology and 
Experimental Therapy (IIET, Poland), 
and the Félix d’Hérelle Reference 
Center for bacterial viruses of the Uni-
versity Laval (Canada). Recently, the 
Leibniz Institute DSMZ also launched 
the Therapeutic Phage Bank for depo-
sition of phages with therapeutic in-
terest.
Recommended targets  
for clinical trials
There is a clear need for well-conduct-
ed, randomized, double blind, place-
bo controlled clinical trials to settle 
the debate on the efficacy of phage 
therapy. Ideally, these trials should 
have the ability to convince the gen-
eral public and alert decision makers 
about the potential benefits of phage 
therapy. We would recommend to set 
up a phage therapy study for the treat-
ment of severe burn wounds infected 
with important nosocomial patho-
gens (ESKAPE bacteria: Enterococ­
cus faecium, Staphylococcus aureus, 
Klebsiella pneumoniae, Acinetobacter 
baumannii, Pseudomonas aerugino­
sa, and Enterobacter species). The 
proposed study set-up builds on the 
already running PhagoBurn FP7 clini-
cal trial (http://www.phagoburn.eu/) 
that focuses on treating burn wound 
patients infected with Escherichia 
coli and P. aeruginosa bacteria. Since 
the general public and politicians are 
already aware of the consequences 
of hospital infections with antibiotic 
resistant “superbugs”, we expect that 
multi-target phage therapy trials could 
serve as a springboard for further ac-
ceptance and re-implementation of 
phage therapy. 
In addition to the aforementioned 
clinical study, we also recommend 
setting up trials that use phages for 
treating urinary tract and prostate in-
fections. Although such targets are 
less attractive in terms of communi-
cation and public awareness, treating 
these infections with phage therapy is 
desirable from a scientific and techni-
cal perspective due to large number of 
patients, and because these patients 
are often infected only by one bacte-
rial pathogen species allowing the use 
of single-phage preparations. 
Based on common practice in 
eastern Europe, we further propose to 
investigate the treatment of infections 
by using a combination of phages 
and antibiotics, which are reported to 
have a synergistic effect in controlling 
bacterial infections [6].
Apart from the discussion on the 
application of phages therapeutical-
ly, the production and application of 
phage cocktails for decontaminating 
hospital environments is another op-
portunity that could be further ex-
plored: A previous study conducted 
by the Eliava Institute showed that 
phage decontamination of the hos-
pital environment resulted in a lower 
incidence of nosocomial infections 
(Alavidze, Z., personal communica-
tion). Moreover and independent from 
our recommendations in Table 2, such 
specific prophylactic applications that 
do not involve direct contact between 
4	 ©	2016	The	Authors.	Biotechnology	Journal	published	by	Wiley-VCH	Verlag	GmbH	&	Co.	KGaA,	Weinheim
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phages and patients are not expect-
ed to be hindered by regulatory and 
safety hurdles. As a part of future pro-
phylactic studies, we would recom-
mend to investigate the emergence 
and spread of bacterial phage resist-
ance in the hospital environment and 
how it relates with the composition 
and number of phages used in the de-
contaminating phage cocktail. Such 
an approach is commonly practiced in 
the area of food safety [7]. 
Genetically engineered phages
Although phage therapy has been 
applied for more than 90 years by 
isolating and finding efficient phage 
species from environment, we now 
live in the era where we can directly 
edit phage genomes. For example, 
phages modified by the CRISPR-Cas 
genome editing tool have been dem-
onstrated to be an effective mean in 
targeting and sensitizing antibiotic 
resistant bacteria by elimination of 
antibiotic resistance-conferring plas-
mids [8]. Genetic engineering could 
also be used to alter phage host range 
via reconstruction of the tail fibers 
[9]. Another option is the incorpo-
ration of a secondary payload into 
the phage genome, such as biofilm 
degrading enzymes or antimicrobial 
peptides, by replacement of nones-
sential phage genomic regions [10, 
11]. Phages could also be engineered 
with antimicrobial agents that attack 
gene networks (e.g. SOS system) of 
antibiotic resistant bacteria. Such en-
gineered phages could be further used 
alongside with antibiotic therapy to 
enhance the performance of antibiot-
ics [12]. Apart from targeting phages, 
genetic engineering technology could 
be applied for the selective removal of 
virulence factors or prophages from 
the host strains, which could further 
increase the safety of phage products. 
This option could also be attractive 
in generating intellectual property 
rights. 
In line with regulations surround-
ing genetic engineering in general, 
preventing genetically modified phag-
es to escape into the environment is a 
major concern. To account this worry, 
phages could be modified to limit their 
replication upon infection of a host to 
ensure that once their task is com-
pleted, new virions are not released 
into the environment (Phages in Inter­
action IV, Leuven, BE 015). 
Concluding remarks
Here we have given an opinion on the 
potential roles of several active and 
passive stakeholders involved in the 
debate surrounding the acceptance 
and re-implementation of the phage 
therapy. In many countries today, 
phage therapy falls under a legislation 
that does not recognize the specific 
nature of phages as self-amplifying 
and evolving anti-bacterials contrary 
to static chemical drugs. As a conse-
quence, the application of phage ther-
apy is still limited and its full potential 
has not been properly explored. The 
cost of delaying the implementation of 
phage therapy is enormous given the 
increasing prevalence of antibiotic 
resistant bacteria and its associated 
economic burden and public health 
consequences for the society.
We have also proposed a minimal 
list of safety and release requirements 
for phage cocktails. Patients’ safety 
is not debatable and appropriate risk 
assessment of phage products and 
their subsequent application in phage 
therapy should be monitored continu-
ously. In our opinion, such risk as-
sessment should cover not only the 
potential adverse effects of the phage 
therapy but also the costs of not-ap-
plying phages as an alternative treat-
ment when the antibiotics fail to treat 
resistant infections. For instance, the 
E. coli outbreak that caused the death 
of more than 50 patients in the Ger-
many in 2011 [13] is a clearly higher 
cost compared to any potential risks 
phage therapy has ever been reported 
to cause.
Genetic engineering of phages 
could, on the one hand, offer vast 
opportunities for phage therapy. On 
the other hand, unintended release 
of genetically modified phages in the 
environment raises several concerns 
for the use of GM organisms. Thus 
at the time being, we propose that 
re-implementing phage therapy in its 
traditional form would already offer 
enough for creating new opportuni-
ties to treat bacterial infections. 
We finally argue that new or adapt-
ed regulatory frame-works should ac-
knowledge the inherent advantages 
of phages over antibiotics in terms of 
their sustainability (ever increasing 
phage infectivity via phage-bacteria 
coevolution) and their host specificity 
(no collateral damage to benign com-
mensal flora). Recently, Verbeken et 
al. [14] evaluated possible regulatory 
pathways for the (re)introduction of 
phage therapy in a way that maintains 
its effectiveness, safety and as well 
its inherent advantages, evolvability 
and specificity. In addition to the pro-
posal to classify phages under the 
medical devices frame-work, a more 
straightforward option would be to 
classify bacteriophage cocktails un-
der the Medicinal Products Directive 
2001/83/ EC that already comprises 
various pharmaceutical products and 
treatments which are different from 
the classical chemical molecules. 
Alternatively, a new Phage Direc-
tive could be created, e.g. “Directive 
Concerning the Therapeutic Use of 
Natural Phages” [14]. A new adapted 
regulatory frame-work should also in-
clude an accelerated time frame for 
developing phage preparations; while 
the regular timeline for a classical 
drug approval is often years, the de-
velopment of a “new” natural phage 
product could take place within days 
or weeks.
This multidisciplinary expert pan-
el opinion on bacteriophage therapy 
has been written in the context of 
a society that is confronted with an 
ever-increasing number of antibiotic 
resistant bacteria. This report aims 
to contribute to the opinion formation 
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of all mentioned stakeholders, espe-
cially (supra)national authorities in 
their role as definitive stakeholder, on 
how to develop an infrastructure and 
legislation that paves the way for the 
acceptance and re-implementation of 
bacteriophage therapy. 
The expert round table participants 
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I. Kurtboke, M. Kutateladze, S. McCal­
lin, M. Merabishvili, G. Mgaloblishvili, 
L. Nadareishvili, N. Nikolaishvili, 
D. Nizharadze, R. Pantucek, J. Pirnay, 
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mation.
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